Nkarta (NKTX) Non-Current Debt (2020)

Nkarta's quarterly Non-Current Debt came in at $10.2 million in Q2 2020.

Nkarta has reported Non-Current Debt for 1 years, with the latest figure at $10.2 million in Q2 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 319.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 105.94 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 1.99 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Nkarta 232.80 Mn 232.80 Mn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2020 10.20 Mn
Jun 30, 2020 10.20 Mn